Dr Ridker discusses new findings from the JUPITER trial which were initially released at the American College of Cardiology meeting in March ‘09.

As was previously reported in the New England Journal of Medicine, treatment with rosuvastatin significantly reduced vascular event rates in individuals with normal levels of LDL cholesterol and elevated hsCRP levels. In the present pre-specified analysis, the objectives were to compare clinical outcomes according to achieved levels of LDLC and hsCRP after adjustment for all available baseline clinical characteristics including entry levels of LDLC, HDLC and hsCRP; and to evaluate whether clinical outcomes according to achieved lipid and hsCRP levels are altered by substituting ApoB or the ApoB:ApoA ratio for LDLC.

Dr. Ridker shows the data recently published in The Lancet, demonstrating that achievement of low target levels of both LDLC and hsCRP was associated with improved event-free survival compared to achieving neither target, or low LDLC alone. When substituting ApoB or the ApoB:ApoA ratio for LDLC similar findings were observed.

Copyright © 2009 E-MedHosting.com Inc.

After viewing this presentation the participant will be able to discuss:
- Main findings of the JUPITER trial
- Clinical outcomes according to achieved levels of LDL-C and hsCRP after adjustment for baseline characteristics
- Clinical outcomes according to achieved hsCRP and other lipid values substituted for LDL-C

Paul M Ridker, M.D., Eleanor Danielson, M.I.A., Francisco A.H. Fonseca, M.D., Jacques Genest, M.D., Antonio M. Gotto, Jr., M.D., John J.P. Kastelein, M.D., Wolfgang Koenig, M.D., Peter Libby, M.D., Alberto J. Lorenzatti, M.D., Jean G. MacFadyen, B.A., Børge G. Nordestgaard, M.D., James Shepherd, M.D., James T. Willerson, M.D., Robert J. Glynn, Sc.D., for the JUPITER Study Group. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein N Engl J Med. 2008 Nov 20;359(21):2195-207.

Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Trial Study Group. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial Lancet. 2009 Apr 4;373(9670):1175-82.